Critical appraisal of omega-3 fatty acids in attention-deficit/hyperactivity disorder treatment by Konigs, A. & Kiliaan, A.J.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/167692
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
© 2016 Königs and Kiliaan. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Neuropsychiatric Disease and Treatment 2016:12 1869–1882
Neuropsychiatric Disease and Treatment Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1869
R e v i e w
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/NDT.S68652
Critical appraisal of omega-3 fatty acids in 
attention-deficit/hyperactivity disorder treatment
Anja Königs
Amanda J Kiliaan
Department of Anatomy, Donders 
institute for Brain, Cognition & 
Behaviour, Radboud University 
Medical Center, Nijmegen, the 
Netherlands
Abstract: Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental 
disorder. The classical treatment of ADHD where stimulant medication is used has revealed 
severe side effects and intolerance. Consequently, the demand to search for alternative treatment 
has increased rapidly. When comparing levels of omega-3 polyunsaturated fatty acids (ω-3 
PUFAs) in ADHD patients with those in age-matching controls, lower levels are found in ADHD 
patients’ blood. ω-3 PUFAs are essential nutrients and necessary for a proper brain function and 
development. Additionally, there are strong indications that ω-3 PUFA supplements could have 
beneficial effects on ADHD. However, the results of ω-3 PUFA supplementation studies show 
a high variability. Therefore, we reviewed recent studies published between 2000 and 2015 to 
identify effective treatment combinations, the quality of design, and safety and tolerability of 
ω-3-containing food supplements. We searched the databases MEDLINE, PubMed, and Web 
of Science with keywords such as “ADHD” and “ω-3/6 PUFA” and identified 25 studies that 
met the inclusion and exclusion criteria. The results of these ω-3 PUFA studies are contradic-
tory but, overall, show evidence for a successful treatment of ADHD symptoms. Tolerability 
of the given supplements was high, and only mild side effects were reported. In conclusion, 
there is evidence that a ω-3 PUFA treatment has a positive effect on ADHD. It should be added 
that treatment could be more effective in patients with mild forms of ADHD. Moreover, the 
dosage of stimulant medication could be reduced when used in combination with ω-3 PUFA 
supplements. Further studies are necessary to investigate underlying mechanisms that can 
lead to a reduction of ADHD symptoms due to ω-3 PUFA treatments and also to determine 
the optimal concentrations of ω-3 PUFAs, whether used as single treatment or in combination 
with other medication.
Keywords: ADHD, ω-3 fatty acids, treatment, DHA, EPA
Introduction to the emerging use of omega-3 
in attention-deficit/hyperactivity disorder
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder, 
which has its onset in childhood but can also persist until adulthood.1 The overall pooled 
prevalence of ADHD in the world is 7.2% but differs between sex and age.2–4 In general, 
prevalence of ADHD is higher in males than in females and is most common in school-
aged children. On the basis of criteria stated in the Diagnostic and Statistical Manual 
of Mental Disorders (DSM), ADHD patients can be divided into three groups: mainly 
inattentive, mainly hyperactive/impulsive, or a combination of both.1 The diagnosis 
is based on a number of age-dependent symptoms of inattention and/or hyperactivity/
impulsivity that should occur for a period of at least 6 months. These symptoms often 
lead to severe problems in social behavior as well as in peer relationships. For ADHD 
patients, social life in a family environment and at school/work is therefore difficult. 
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Furthermore, ADHD is often accompanied with learning 
difficulties and mood and behavior disorders.5 Problems in 
social life are the main reason for ADHD treatment.
One of the most commonly used treatments for 
ADHD is the stimulant drug called methylphenidate. Due 
to side effects and unknown long-term effects, however, 
there are concerns about the use of methylphenidate.6 These 
concerns are the main reason for families to postpone meth-
ylphenidate treatment for months to years after a confirmed 
diagnosis of ADHD by a physician. The most important 
reason for families to start using methylphenidate as treat-
ment for ADHD is the ultimate urge to solve problems at 
school, work, and home. This kind of stimulant medication 
is only treating symptoms however, and not the cause. This 
means that the drug is only effective for a couple of hours 
after intake (half-life time of intermediate-release meth-
ylphenidate is 2–4 hours) but will not change the situation 
over the long term.7 Studies have shown that stimulant drugs 
provoke mild side effects in most patients but also cause 
severe side effects, such as decreased appetite, insomnia, 
and headaches.8,9 These general concerns and side effects of 
the stimulant treatment clearly accentuate the need to search 
for alternative and less harmful treatments for ADHD. The 
best known alternative treatment is supplementation with 
omega-3 polyunsaturated fatty acids (ω-3 PUFAs).
It is interesting to use ω-3 PUFAs as treatment for 
ADHD since ADHD patients in general show a lack of ω-3 
PUFAs.10–13 To understand the function of ω-3 PUFAs, the 
family of ω-6 PUFAs also need to be considered. The pre-
cursors of both ω-3 and ω-6 families are essential nutrients, 
which means that they cannot be produced by the body 
itself and should be obtained via dietary intake. In addition 
to the reliance on intake of essential PUFAs, processing of 
the precursors is inefficient in humans.14 During the Paleo-
lithic period, the diet provided sufficient ω-3 PUFAs due 
to the high intake of fish. The ratio of ω-3 to ω-6 PUFAs was 
therefore high. In the western diet, the ratio is low due to 
an increase in ω-6 PUFAs and decrease in ω-3 PUFAs.15–17 
Furthermore, ADHD is multifactorial and depends on 
genetic background on the one hand, and, for a large part 
on environmental factors on the other hand. Reduced ω-3 
PUFAs levels in ADHD could be an interesting additional 
environmental factor because these deficiencies clearly have 
the greatest impact during the development of the central 
nervous system. This is also the time of onset of ADHD. 
This leads to the question whether a food supplement con-
taining ω-3 PUFAs can serve as an alternative treatment 
for ADHD, taking into consideration that there are less 
side effects, a higher efficiency and less concerns about the 
impact on health. The purpose of this article is to critically 
review recent literature on ω-3 PUFAs treatment for ADHD, 
to determine 1) effective treatment combinations, 2) the 
quality of design of the clinical trials, and 3) the safety and 
tolerability of the food supplements.
Rationale for ω-3 in ADHD
To clarify the hypothesis that supplements containing ω-3 
PUFAs could be used as effective ADHD treatment, the role 
of ω-3 PUFAs in the healthy brain in comparison with the 
brain of an ADHD patient needs to be discussed. When pre-
cursors of ω-3 and ω-6 long chain PUFAs (LCPUFAs) enter 
the body, they enter the same enzyme pathway. The precursor 
α-linolenic acid (ALA) belongs to the group of ω-3 PUFAs 
and can be found in flax and in small amounts in soybeans, 
canola oil, and green leafy vegetables. The precursor can be 
converted into docosahexaenoic acid (DHA), which forms an 
important part in the production of phospholipids in neuronal 
membranes in the brain. DHA is responsible for fluidity and 
permeability of the neuronal membrane. High concentrations 
are found particularly in synapses, which makes DHA neces-
sary for the function of neurons. An important intermediate 
is eicosapentaenoic acid (EPA), which is responsible for the 
production of eicosanoids. These eicosanoids can function as 
anti-inflammation signaling molecules.18 High concentrations 
of DHA and EPA are found in fish and fish oil.
Eicosanoids are also responsible for the regulation of 
the interaction of the ω-3 and ω-6 PUFA pathways. In addi-
tion to eicosanoids, the ratio between ω-3 and ω-6 PUFAs 
is also responsible for the regulation of both the pathways. 
A high intake of ω-6 PUFAs may inhibit the production 
of ω-3 PUFAs from its precursor and benefit processing 
of ω-6 PUFAs. The ω-6 PUFAs precursor is linoleic acid 
(LA) and is transformed into arachidonic acid (AA) as an 
important intermediate. In addition to EPA, AA produces 
anti-inflammatory eicosanoids, which can also be found 
in reasonable amounts in neuronal membranes.18 The final 
product is docosapentaenoic acid (DPA), which has inflam-
matory effects.18
Several arguments why ω-3 PUFAs may serve as good 
candidates for the treatment of ADHD can be found in 
literature. These arguments are based on the biochemical 
and physiological functions of ω-3 PUFAs. First, mem-
branes of neurons contain high amounts of ω-3 and ω-6 
PUFAs, especially DHA and AA, for proper neuronal func-
tion. The amount of ω-3 and ω-6 PUFAs affects the fluidity 
of the membrane, which could affect neurotransmission, 
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permeability, as well as structure and function of membrane-
bound proteins. In blood and plasma of ADHD patients, the 
level of ω-3 PUFAs is lower than in age-matching controls. 
These lower levels can be found in children, adolescent, and 
adults.10–13 Postmortem measurements of the cortex showed 
that DHA concentration in a healthy brain increases until the 
age of 18 years.19 Furthermore, ω-3 PUFAs have an important 
function in brain development.20–23 This could explain why 
ω-3 PUFA deficiency during development has a wide impact 
on the function and development of the brain.
The second argument concerns the ratio of ω-3/ω-6 
PUFAs in blood and plasma cells, which is lower in patients 
with ADHD. The relatively higher amount of ω-6 PUFAs 
may increase neuroinflammation. Since ADHD patients and 
controls consume similar amounts of ω-3 and ω-6 PUFAs, it 
is likely to presume that there are other causes for this change 
in ratio.10,13 One possible cause could be that processing of 
PUFAs is less effective in patients with ADHD.13 Common 
signs of essential fatty acid deficiency in ADHD patients are 
skin rashes and increased thirst.10 It is presumed that these 
symptoms are due to a deficiency in ω-6 PUFAs.24 In any 
case, it should be added that there is no competition between 
ω-3 and ω-6 PUFAs during uptake but only at processing 
level.25 This offers the opportunity to increase the amount 
of ω-3 PUFAs through higher dietary intake.
Search methodology
The following databases were searched between January 2000 
and March 2016: MEDLINE, PubMed, and Web of Science. 
For this search, keywords such as Attention Deficit Hyper-
activity Disorder (ADHD), ω-3 and ω-6 (long chain) poly 
unsaturated fatty acids (LCPUFAs), DHA, EPA, γ-linolenic 
acid (GLA), ALA, and fish oil were used. Other relevant infor-
mation was also searched in references of reviews, studies, 
and meta-analyses. Inclusion criteria for trials were 1) a treat-
ment with ω-3 PUFAs or in combination with ω-6 PUFAs, 2) 
a study design of open-labeled studies excluding a placebo 
group or double-blind studies including a placebo group, 
and 3) a diagnosis or suspicion of ADHD. Studies where 
ADHD was accompanied by the presence of a comorbidity 
were also included. As additional treatment, antioxidants 
such as vitamin E and carriers such as phospholipids, which 
improve the availability of PUFAs for the body, were 
included as well. Trials related to other deficiencies in combi-
nation with ω-3 PUFA deficiency such as zinc are excluded. 
Titles and abstracts of identified articles were controlled for 
inclusion and exclusion criteria. A flow diagram of the study 
selection is provided in Figure 1.
Results
In several studies, it has been indicated that a supplemen-
tation of ω-3 PUFAs has a beneficial effect on ADHD 
symptoms.26–30 However, results of these studies show a 
high variability and inconsistency about its effect on ADHD. 
In this review, only studies that were published between 2000 
and 2015 are included. First, general information about all 
selected trials is provided followed by separate discussion 
on the results of each trial. These studies are divided into 
open-labeled trials without the presence of a placebo group 
(Table 1) and double-blind trials with the presence of a pla-
cebo group (Table 2).
The subjects who participated in these trials were mostly 
school-aged children from 6 to 13 years old. In fact, the total 
age range was 3.5–18 years. The predominant sex is male 
which is in accordance with the prevalence of ADHD in the 
population. In most cases, physicians officially diagnosed 
these children with ADHD in accordance with DSM-IV 
criteria.31–33 An alternative method used for the diagnosis 
of ADHD was via the criteria set in the Conners ADHD 
Index or Conners Rating Scale; scores higher than the 90th 
percentile in the parent-rated were used.28,29,34,35 Some studies 
also included children who had not been officially diagnosed 
with ADHD but who showed signs similar to children 
with ADHD.11,27–29,36–38
When taking comorbidity into account, it is evident 
that there are many common comorbid conditions associ-
ated with ADHD, which makes a homogeneous subject 
group difficult. In most studies, children with comorbidi-
ties of severe disorders were excluded. Examples of these 
disorders are neurological disorders and diseases such as 
epilepsy, mental retardation, autism spectrum disorder, 
mental insufficiency, encephalic malformations, including 
mechanical damage like a head injury leading to tempo-
rary loss of consciousness. Milder comorbidities such as 
Figure 1 Flow diagram of study selection.
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learning difficulties, developmental coordination disorder, 
oppositional defiant disorder, and conduct disorder were not 
excluded.31,34,36 Often, children were already treated both for 
ADHD and for the comorbid disorder before participating 
in studies with ω-3 PUFAs. In most studies, children were 
asked to cease taking stimulant medication for the period 
of study. In case of treatment with stimulant medication, a 
washout period was often added.
The number of included subjects taking part in these 
studies varied considerably, that is, from 9 to 697 subjects. 
Some of the studies involving smaller number of subjects 
were pilot studies, thus explaining the small subject group 
in some cases.11,26,36,39–41 Studies reported various duration; 
from 8 up to 36 weeks. Trial length of most studies varied 
from 8 to 16 weeks. During this period of time, children’s 
behavior was investigated; questionnaires were completed 
by parents and/or teachers and/or investigator. In addition, a 
few studies included cognitive tests to investigate the atten-
tion of the children. In some of these studies, the fatty acid 
profile of blood and/or plasma cells as well as physiological 
parameters were included, in order to control side effects of 
food supplements. Side effects are discussed in more detail 
in the section “Safety and tolerability”.
Results of nonplacebo-controlled trials
The effects of PUFAs in ADHD symptoms were inves-
tigated in five open-labeled studies excluding placebo 
groups.11,26,38,39,42 All the five studies showed improvement 
in ADHD symptoms in behavioral questionnaires, which 
were rated by parents and/or investigators. In three of these 
studies, improvement in behavior was found, in addition to 
a positive effect in the blood fatty acid profile.11,39,42 In the 
study of Barragán et al,26 an interesting design was used: 
a comparison was made between 1) a food supplement 
consisting of PUFAs, 2) stimulant medication, and 3) a com-
bination of both.26 The food supplement consisted of 174 mg 
DHA, 558 mg EPA, and 60 mg GLA. Results showed that 
a combined treatment of a food supplement with stimulant 
medication is not more effective than when merely taking 
methylphenidate, but resulted in less side effects. Food 
supplementation-only treatment is less effective than when 
taking only stimulant medication or taking a combination of 
both. This is a valuable information for scientists involved 
in designing less harmful treatments for ADHD. It should 
be added that there were variations in diet used in these 
reviewed studies. In four studies, a combination of DHA and 
EPA was used. In all the studies, DHA content was lower 
than that of EPA.
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ω-3 fatty acids as ADHD treatment
In comparison with other studies, the dietary compo-
sition in the study of Sorgi et al39 and Germano et al11 is 
remarkable because of the use of high amounts of EPA 
and DHA. The supplement contained 5,400 mg DHA and 
10,800 mg EPA/2,202 mg DHA and 4,149 mg EPA, while 
other studies used a maximum of 174 mg DHA and 558 mg 
EPA. In the remaining study, ALA was used instead of DHA 
and EPA, which is, in fact, a precursor of DHA and EPA. 
This is surprising because it is presumed that the processing 
of the precursors of ω-3/6 fatty acids in the human body 
is less effective.14
Results of double-blind placebo-
controlled trials
An overview of the double-blind trials with placebo groups 
can be found in Table 2. These studies are classified in 
accordance with the different compositions used in the 
PUFA supplements. There is only limited information pro-
vided about the rationale for the used PUFA concentrations 
provided to the participants. Most studies used combinations 
that were already successfully tested in earlier trials. At the 
moment, there are no studies that performed dose response 
of ω-3 PUFAs treatment in ADHD. It is of importance that 
future studies will address this.
Treatment based on ω-3 LCPUFAs only
ω-3 LCPUFAs treatment was tested in four studies.30,31,37,43,44 
In all these studies, the majority of children was treated with 
stimulant medication. The used type and amount of ω-3 PUFA 
differed between trials: In one study, only DHA (345 mg per 
day), in combination with a prescribed stimulant medica-
tion, was used.31 This study failed to show improvement in 
ADHD symptoms on the basis of measurements with regard 
to attention and impulsivity and parent-rated behavior.31 
Three other studies showed a significant improvement in 
some ADHD symptoms: Hirayama et al37,43 found improve-
ment in parent-rated hostility and teacher-rated aggression 
using a treatment of 514 mg DHA and 100 mg EPA per day. 
Six subjects (15%) used stimulant medication besides the 
food supplement. A treatment with 195 mg DHA, 635 mg 
EPA, 100 mg other ω-3 FA in combination with stimulant 
medication led to improvement in scores on the parent-rated 
Conners’ Abbreviated Symptom Questionnaires, as well as 
a decrease in inflammation and oxidative stress.44 The study 
of Bos et al30 demonstrated improvement after treatment in 
both the ADHD group and the control group as based on the 
parent-rated Child Behavior Checklist. The treatment used 
consisted of 650 mg DHA and EPA.
In conclusion, single treatment with DHA alone does 
not show promising results.31 However in this study, all the 
participants were taking stimulant medication while assessing 
behavior.45 The stimulant medication was able to ameliorate 
behavioral symptoms thereby leaving little room for further 
improvement by DHA. On the other hand, a combination of 
DHA with EPA resulted in improvement of some ADHD 
symptoms.30,37,43,44 The results of Hirayama et al37,43 were not 
included in this conclusion because of the subject population 
that was used; the study comprised eight subjects (20%) of 
whom diagnosis of ADHD is arbitrary and not clear whether 
they could be diagnosed with ADHD, if rated by DSM-IV 
criteria. Furthermore, the treatment with stimulant drugs 
was inconsistent, and there was a high percentage of vari-
able comorbidities, for example, subjects with Asperger’s 
syndrome, conduct disorder, learning disorder, or mood 
disorder were included. Moreover, the study was carried 
out in Japan where intake of ω-3 fatty acids is high due to a 
high average consumption of fish.45,46 In this study, baseline 
fatty acid levels in blood were neither analyzed nor com-
pared with values of ADHD patients in other countries. The 
experiment was also underpowered due to its small sample 
size. An interesting aspect of this study was the treatment 
that was chosen; instead of providing subjects supplements 
with fish oil or other fatty acids, the supplements were put in 
fermented soybean milk, bread rolls, and steamed bread, pri-
marily to mask the taste of fish oil. Another study where other 
food products were used concerns the study of Bos et al30 
supplements or placebos were put in margarine.
Trials with both ω-3 LCPUFAs and vitamin e
In four trials, vitamin E was added to ω-3 LCPUFAs as a mea-
sure to protect against easy oxidization of LCPUFAs.32,34,35,47–49 
In all these studies, a combination of 10–15 mg vitamin E 
with ω-3 LCPUFAs was given to children who did not take 
any stimulant treatment. In two studies, a food supplement 
with a low amount of DHA and a high amount of EPA 
(2.7 mg DHA +500 mg EPA/120 mg DHA +600 mg EPA) 
was used.32,47 In general, these studies failed to show positive 
effects. Based on the teachers rated Conners Rating Scale, 
only one study found improvement in one, later-defined 
subgroup as far as oppositional behavior and hyperactivity/
impulsivity are concerned.32 Two other studies by Milte 
et al34,35 in 2012 and 2015 compared different ratios of 
DHA to EPA: 1:10 (108 mg DHA, 1,109 mg EPA) and 4:1 
(1,032 mg DHA, 264 mg EPA). These studies also failed to 
show amelioration of ADHD symptoms. However, improved 
fatty acid profile in erythrocytes was correlated with 
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improvement in outcome measures. The 2012 study showed 
a correlation with improvement in word reading, parent-rated 
oppositional behavior, and anxiety/shyness.35 This correlation 
was even stronger in the subtype with learning difficulties. 
The study performed in 2015 revealed correlations with 
improvement in literacy, attention, and behavior. It has to 
be mentioned that there were inconsistencies in compliance 
in the study performed in 2012. The highest compliances 
were found in the treatment groups that also showed the 
largest improvement in blood fatty acid levels. There are 
some other limitations in this study: an official diagnosis 
of ADHD was lacking in 50% of the children included, and 
also children with comorbidities such as mood or conduct 
disorders were included.
From the four studies aforementioned, it can be sug-
gested that the ratio between DHA and EPA is not the most 
important factor in the treatment against ADHD. This sug-
gestion is supported by a study in which it has been shown 
that processing is, in fact, a vital step.25 This means that it is 
not the ratio, but, in fact, the amount of ω-3 PUFAs which is 
important.25 An addition of vitamin E, together with its anti-
oxidant capacities, did not show any effect either. However, 
some changes in the fatty acid profile in the blood were cor-
related with improvement in outcome measurements.
Trials with ω-3/6 PUFAs
Seven trials included treatments containing both ω-3 and ω-6 
LCPUFAs. In 2002, Richardson et al36 tested a supple-
ment containing 480 mg DHA, 180 mg EPA, 864 mg LA, 
42 mg AA, 3 mg vitamin E, and 8 mg thyme oil. This 
study reported an improvement in the parent-rated Conners 
Rating Scale.36 Subjects were children aged between 8 and 
12 years. All had writing and reading problems and were 
suspected of having ADHD. However, ADHD had not been 
officially diagnosed and, thus, no stimulant medication had 
been prescribed. Another issue is the small sample size of 
29 participants. In another study, a comparable treatment 
was used, but with different amounts: 480 mg DHA, 80 mg 
EPA, 96 mg GLA instead of the precursor LA, 40 mg AA, 
and vitamin E acetate.40 In this study, children were taking 
stimulant medication in combination with the food supple-
ment. Except for an improvement in the ratio of ω-3/ω-6 fatty 
acids in erythrocytes and plasma phospholipids, no other 
effects were found. However, improvement in behavior was 
found in both placebo and treatment group.45 This suggests 
that these effects are not specific for the active treatment. 
Also in this study, the small sample size should be taken into 
account (N=33). In a third study, a high concentration of ω-3 
LCPUFAs (593 mg) and a low amount of ω-6 LCPUFAs 
(361.5 mg) in combination with stimulant treatment were 
used.41 It was not specified which particular unsaturated fatty 
acids were used. After 6 months, a successful reduction in 
behavioral and learning problems was detected and a sig-
nificant improvement was already apparent after 3 months 
of treatment in a subgroup of inattentive subjects. It should 
be noted that this subgroup was defined after the study had 
been completed.
In 2005, Richardson et al27 completed a study in which a 
low DHA and high EPA content with additional ω-6 PUFAs 
was used (174 mg DHA, 558 mg EPA, 60 mg GLA, and 
9.6 mg vitamin E). During experiments, no stimulant medi-
cation was taken by any of the children. Almost the same 
combination of treatment had already been used in three 
other studies (174 mg DHA, 558 mg EPA, 60 mg GLA, and 
10.8 mg vitamin E).28,29,33 When comparing these four studies 
in total, three out of four studies showed a general improve-
ment in ADHD symptoms, such as literacy, and switch and 
control of attention. This was based on information from the 
Conners Rating Scales, completed by teachers and parents. 
The fourth study showed an improvement only in a subgroup 
of inattentive patients, measured by the ADHD Rating Scale 
and Clinical Global Impression of Severity of Illness.33
In summary, a treatment with ω-3 fatty acid DHA and EPA 
in combination with ω-6 fatty acids GLA or LA and vitamin E 
seems to be effective in treating ADHD symptoms.27–29,36,41 
The treatment with 174 mg DHA, 558 mg EPA, 60 mg GLA, 
9.6 or 10.8 mg vitamin E was tested in four studies, which 
led to promising results:27–29,33 Three studies succeeded in 
showing improvement in ADHD symptoms. One of these 
studies and the study supplementing 593 mg ω-3 PUFAs 
and 361.5 mg ω-6 PUFAs reported more improvement in 
the inattentive subtype.33,41 However, these subgroups were 
defined after studies had been completed. In further research, 
it is recommendable to repeat the same treatment but define 
the different subtypes before starting the study and include 
all of these different subtypes in the investigation.
Trials with ω-3 LCPUFAs and phospholipids
Apart from ω-3 fatty acids, phospholipids were also 
included in three of the studies during treatment.50–52 It has 
been demonstrated in animal studies that phospholipids can 
function as carriers for ω-3 LCPUFAs in order to increase 
the availability of the LCPUFAs for uptake in the body.53,54 
Subjects using stimulant medication were excluded in all 
of these three studies. In the trial of Vaisman et al,50 one of 
the following combinations was used; either 95 mg DHA, 
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155 mg EPA, and 550 mg other saturated and unsaturated 
fatty acids or 468 mg phospholipids and 329 mg other fatty 
acids. When checked against the criteria set in the Test of 
Variables of Attention, only the treatment with additional 
phospholipids led to an increase in scores. In another study, 
the concentration of dietary components in the supplements 
used was determined based on the participant’s body weight.51 
For example, children with a body weight between 26 and 
35 kg were treated with 300 mg DHA, 750 mg EPA, 38 mg 
vitamin E, and 50 mg plasma phospholipids. In this particular 
study, the treatment failed to show any effect. However, when 
checked against the criteria set in the parent- and teacher-
rated Conners Rating Scale, another unexpected improvement 
was found in the treatment group as well as the placebo group. 
A major criticism of this study is the small sample size (N=26). 
The study of Manor et al52 used food supplements containing 
40 mg DHA, 80 mg EPA, and 300 mg phosphatidylserine. 
Results did not show any effect, except for improvement in 
the restless/impulsive subscale rating of the Conners Rating 
Scale for parents and the parent impact-emotional subscale 
of the Child Health Questionnaire. One explanation could be 
the small number of participants (N=17).
In conclusion, there is little evidence that a combination 
of phospholipids and ω-3 FA can affect ADHD symptoms. 
As shown in the study of Manor et al,52 there is only little 
evidence as to whether this has an effect on treating ADHD. 
This study included behavioral ratings from teachers who 
were not trained to rate ADHD symptoms. These teachers had 
up to 42 children in a classroom, and some of these teachers 
were replaced during the period of study. More positive 
effects could possibly be found when improving the rating 
quality to be filled in by teachers. Further studies should be 
performed before drawing any other conclusions about the 
effect of ω-LCPUFAs in combination with phospholipids 
on ADHD symptoms.
Trials with ω-3/ω-6 LCPUFA precursors
Precursors of ω-3/ω-6 LCPUFAs were used in two studies.55,56 
In the first study, a combination of 120 mg ALA, 480 mg LA 
in combination with 190 mg mineral oil and 10 mg vitamin E 
was used, but this combination failed to show any improve-
ment in ADHD symptoms.55 The second study used a much 
higher amount of ALA (1,000 mg ALA including 320 mg 
LA, 400 mg oleic acid, 120 mg palmitic acid, and 40 mg 
stearic acid), but lacked any positive results as well.56 This 
supports the argument that intake of ω-3/ω-6 PUFA precur-
sors has a lower efficiency than intake of ω-3/ω-6 LCPU-
FAs, probably due to the low processing efficiency of the 
precursors.14 Furthermore, there is evidence that ALA-rich 
diets reduce the conversion rate from ALA to EPA, while it 
increases the oxidation rate of ALA.57
General conclusion
The results of the studies described above are inconsistent. 
All trials without placebo group showed positive results. These 
results should be interpreted with care, however, because a 
placebo group is missing. The study of Barragán et al26 had 
an interesting design in which effects of a food supplement 
were compared to effects of stimulant medication as well as 
the combination of both. It would be helpful to repeat this 
study in a double-blind design including the use of a placebo 
group in order to get more information about the possibility 
to reduce the amount of given stimulant medication.
Adding a placebo group and using a double-blind study 
design only led to positive results in few studies. There was 
little evidence that the single ω-3 LCPUFAs treatment had any 
effect on ADHD symptoms. Studies that had shown positive 
effects used very small number of participants (n=9) or had 
a high variability in ADHD diagnosis in combination with 
comorbidities.37,44 The study of Bos et al30 demonstrated a pos-
itive effect both in the ADHD group and in the control group 
when using an active treatment of 650 mg DHA and EPA. 
This suggests that an improvement of behavior through addi-
tional ω-3 LCPUFAs is not ADHD-specific. Adding vitamin 
E to ω-3 LCPUFAs did not show any convincing results 
either. Only in one study, an improvement in the hyperac-
tive and impulsive subgroup could be found.32 The division 
in subgroups was however exerted after finishing the study. 
In order to obtain more reliable results, this study should be 
repeated after a clear division of subtypes has been realized 
before the start of the study, thus resulting in getting more 
information about the effect of ω-3 treatment in combination 
with vitamin E in the hyperactive/impulsive subtype.
Treatment with a combination of ω-3 and ω-6 LCPUFAs 
showed much more promising results. Positive results on 
ADHD symptoms were found in five studies. In several 
studies, a treatment with 174 mg DHA, 558 mg EPA, 60 mg 
GLA, 9.6 or 10.8 mg vitamin E particularly showed promis-
ing results.27–29 In four of these studies, however, children 
without ADHD diagnosis were also included. The only study 
that used the same treatment in officially diagnosed ADHD 
patients did not show any effect.33 On the basis of two ques-
tionnaires, the only improvement could be detected in the 
inattentive subtype.33 On the whole, studies where a combi-
nation of ω-3 and phospholipids was used, showed negative 
results, except for the study of Manor et al.52 Even though the 
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last combination with ω-3 and ω-6 precursors failed to show 
any improvement during testing. This outcome reinforces the 
idea that the processing mechanism in the human body has 
a low efficiency for ω-3 and ω-6 precursors.14
Critical analysis of the study design
Sample size
A general discussion point is the underpowering of some 
the studies due to small number of subjects, which makes 
it difficult to show any effect whatsoever.58 In order to get 
sufficient statistical power, Bloch and Qawasmi59 set up a 
meta-analysis in which they calculated a sample size of at 
least 330 participants. This is especially a problem in studies 
where a heterogenic patient population is used. Heteroge-
neity in patient groups is created by different subtypes of 
ADHD, different comorbidities, inconsistency in the treat-
ment of ADHD with stimulant medication, and differences 
in age and sex.
Age and sex
The age of the participants ranged from 3.5 to 18 years. The 
majority of the children were school-aged between 6 and 
13 years. This age range covers all ages where ADHD occurs 
the most. However, ADHD persist also until adulthood, and 
it would be useful to include also subjects .18 years in trials 
with ω-3-containing food supplements.
One should also carefully consider conclusions drawn 
about differences in sex because there are mostly more male 
than female participants included in the trials. A study with 
ω-3 PUFA supplementation in rats showed that there are 
sex differences concerning hyperactivity and impulsive-
ness symptoms; a clear improvement in hyperactivity and 
impulsiveness symptoms could be detected in male rats, 
whereas in females, there were no effects or oppositional 
effects instead.60 The changes in male rats were associated 
with changes in the neurotransmitter turnover in the brain. 
Furthermore, the conversion efficiency of ALA into EPA 
and DHA seems to be higher in women than in men.61,62 
This is in line with the higher prevalence of ADHD in men 
than in women. The study was performed with reproductive 
women and suggested a potential effect from estrogens on 
the conversion from ALA into DHA. These results suggest 
that it is more important for men to consume the intermediate 
EPA and final product DHA than their precursor ALA, due 
to the low efficiency of ALA processing. It was proven that 
a higher intake of ALA failed to show an increased amount 
of DHA in the erythrocytes membrane in men while there 
was a successful conversion to DHA.62 Another study sug-
gested differences between women and men in processing 
speed and physiological needs.25 The influence of estrogen 
was also mentioned here.
Treatment
The composition and the amount of the different dietary lipid 
components in the supplements varied between the studies. 
This makes comparison of the results of different studies 
difficult. To determine effective treatment compositions, 
dose–response trials should also be performed in future stud-
ies. Furthermore, there is only limited information provided 
on which a certain composition was based. Often, treatment 
compositions from earlier studies were reused. In addition, 
the use of food supplements in participants on stimulant 
medication has to be considered: it is difficult to find the 
effects of supplements on top of the improvement due to 
stimulant medication. Also the baseline levels of ADHD 
symptoms can be biased because the stimulant medication 
already suppresses the symptoms of ADHD.
Study period
Trials usually lasted 8 or 12 weeks. In comparison with this, 
the 36-week study of Barragán et al26 was really long. The 
length of the studies should depend on the recovery time 
of the fatty acid profile both in the blood and in the brain. 
Evidence from a rat study in which DHA recovery was 
measured after DHA deficiency showed that the level of 
recovery in serum is 93% after 4 weeks and 106% after 
8 weeks.63 Brain recovery reached a lower percentage of 
merely 80% after 8 weeks. Additionally, it should be consid-
ered that blood fatty acid profiles may be not representative 
for brain fatty acid contents, especially not in subjects who 
are younger than 18 years.19 Moreover, long-term effects 
should be tested in periods lasting much longer than 8 weeks. 
The study of Perera et al41 measured the effect of treatment 
after 3 and 6 months. In general, they found a reduction in 
behavioral and learning difficulties after 6 months.41 In the 
inattentive subtype, this was already visible after 3 months. 
This indicates that treatment effects could be seen much later 
than in 8 up to 12 months, a period of time that is used in most 
studies. Taking trial lengths together with the recovery time 
of fatty acid profiles into consideration suggests that trials 
should not be shorter than 8 weeks. A longer treatment is 
advisable, however, in order to find effects that can only be 
detected after a longer period of supplementation and that 
depend on the recovery of fatty acid profiles.
Assessment
In general, a low number of different measurements was used 
in the studies which, moreover, varied between the trials. 
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This makes comparisons between the studies difficult. In 
most cases, only two or three different questionnaires or 
tests were conducted to investigate ADHD symptoms. Some 
studies additionally measured the fatty acid profile in the 
blood which is also considered as appropriate estimation 
of the brain fatty acid content. However, there is evidence 
that under the age of 18, the blood fatty acid content is 
correlated to the brain fatty acid content only to a certain 
extent.19 Questionnaires often depended on ratings given by 
parents or teachers. A problem with the parents’ ratings is 
the comprehension of the questionnaires. When completing 
the Child Behavior Checklist, Widenhorn-Müller et al47 
found that parents might have problems understanding the 
questions correctly.47 Parents were asked to rate and explain 
the children’s behavior. Ratings were given, but the descrip-
tion of behavior was often missing due to a possible lack of 
comprehension. This problem was solved in the study of 
Germano et al11 in which parents were trained to rate their 
child’s behavior.11 It should be considered that all question-
naires are subjective, consequently influencing the results. 
Another problem with teacher-rated questionnaires are fac-
tors such as holidays, the occurrence of big pupil groups, and 
only a small number of contact hours with the subject.28,52 In 
trials that were not blinded, prior knowledge of giving active 
treatment could influence the judgment of teachers, parents, 
and physicians alike. In conclusion, trials differed in many 
ways, which makes it difficult to make a comparison and to 
estimate the reliability of results. For future studies, homo-
geneous groups of subjects and a clear division between the 
subtypes are advisable.
Safety and tolerability
To provide an alternative to stimulant medication, it is 
necessary to consider the safety and tolerability of the ω-3 
PUFA food supplements. Food supplements that have been 
described in this critical appraisal showed a good tolerability 
in general. Tolerability can be judged by the dropout rate and 
its reported side effects in relation to aversive events. In all 
these reviewed studies, only a few participants dropped out 
because of aversive events. Most common side effects dur-
ing treatments with an ω-3 PUFA supplement were related 
to gastrointestinal discomfort, such as stomach ache, feeling 
sick, and diarrhoea.28,33,55 Nose bleeds were also reported, but 
far less frequent.28,32,34 One study investigated the safety of 
phosphatidylserine-containing supplements over a period 
of 30 weeks.64 During the first 15 weeks, double-blind and 
placebo-controlled trials were carried out followed by a 
15-week open-labeled extension phase. During the first 
15 weeks, a combination of 300 mg phosphatidylserine, 
80 mg EPA, and 40 mg DHA was given. During the open-
labeled phase, half of this amount was given. Results showed 
no effect on physical parameters and no differences between 
placebo groups and treatment groups. This study concluded 
that the tested treatment was well tolerated.
Tolerability of ω-3 LCPUFAs in ADHD patients has not 
been investigated in studies lasting longer than 36 weeks 
yet.26,28,29 In two studies, lasting 30 and 36 weeks each, a 
treatment of 174 mg DHA, 558 mg EPA, and 60 mg GLA 
and in one study 10.8 mg vitamin E was given. Gastroin-
testinal discomfort and incidental nose bleeds were side 
effects reported by only some subjects. Two other subjects 
indicated a loss of appetite. Similar side effects, also in rare 
cases, were found in another study with regard to behavioral 
problems in children between 8 and 16 years.65 During this 
study, a double-blind trial with 100 participants in total was 
carried out. These participants were divided into a placebo 
group and a treatment group. Treatment consisted of a 
combination of 300 mg DHA, 200 mg EPA, 400 mg ALA, 
and 100 mg DPA. It can be noted that different quantities of 
ω-3 LCPUFAs were given in the reviewed studies. Toler-
ability of the food supplements did not seem to be affected 
however. Moreover, the use of higher amounts of LCPUFAs 
such as 2,202 mg DHA, 4,149 mg EPA, 461 mg ω-6, and 
1,137 mg other fatty acids or 5,400 mg DHA and 10,800 mg 
EPA were well tolerated by the participants.11,39 Side effects 
of a ω-3 LCPUFAs treatment, in comparison with treat-
ment with methylphenidate, were analyzed in the study of 
Barragán et al.26 The most reported side effect was loss of 
appetite, which was found in 53% of participants taking the 
methylphenidate supplement but only in 27% of participants 
taking an additional food supplement.
When summarizing the tolerability of treatment, it can 
be concluded that there are no reports about severe side 
effects. The most frequently reported side effects were 
gastrointestinal discomfort and incidental nose bleeds but 
in comparison with methylphenidate much less side effects 
occur. Well-known side effects of a treatment with regard to a 
methylphenidate treatment are decreased appetite, insomnia, 
and headaches.8,9 This makes a treatment with ω-3 LCPUFAs 
all the more attractive, as a less harmful alternative for meth-
ylphenidate or any other stimulant medication.
Patient-focused perspective
The most important reason to treat ADHD are problems in 
daily life specifically in the family environment, at school, 
or at work. The most common treatment for ADHD is 
stimulant medication. However, this treatment has often been 
criticized because of its severe side effects. Examples are 
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insomnia and decreased appetite, which are more often 
found in younger and smaller children.9 In children with 
milder forms of ADHD, parents often decide not to give 
stimulant medication because the positive effects do not 
outweigh the side effects. An alternative with less harmful 
side effects is desirable for this group, particularly, resulting 
in making their daily life situations easier and to increase 
the quality of life. In order to reach this goal, treatments 
with food supplements containing ω-3 LCPUFAs could be 
a good solution. This critical appraisal of reviewed studies 
shows that there is a good basis for treatments with ω-3 
LCPUFAs. Compliance rates with regard to these treatments 
were usually high. Most frequently reported problems are 
in comparison to stimulant medication. These were difficul-
ties in swallowing capsules and a dislike of the fishy taste 
of the supplement, which led to a rejection of capsules in 
some cases.34–36,50,56 The studies of Hirayama et al37 and Bos 
et al30 showed a solution to these two difficulties; the fishy 
taste was masked as the supplement was put in soybean 
milk, bread rolls, and steamed bread or margarine, and the 
portions of which were given to patients at a daily basis.37 
However, it is a questionable way of deliver PUFAs this 
way because it has to be considered that margarine could 
increase the risk of oxidations.
Conclusion and place in therapy
This review aimed to identify effective treatment composi-
tions of ω-3 PUFA food supplements, its safety and toler-
ability, and the quality of design of the studies. Reviewed 
studies show inconsistent results. Therefore, clear convincing 
effects of LCPUFAs supplements to decrease ADHD symp-
toms are still lacking. The most promising results are found 
in trials where treatments combining ω-3 and ω-6 LCPUFAs 
were given. The tolerability of supplements was good, and 
only mild side effects such as gastrointestinal discomfort 
and very incidental bleeds were reported. The main issues 
of the study design are small sample sizes, high variability 
in study design, and exerted assessment methods. Future 
studies should include sufficient participants in double-blind 
and placebo-controlled trials. To make the results easier to 
compare, blood fatty acid measurements should be included 
to provide a more reliable assessment of ω-3 baseline levels 
and possible improvements.
Two particular patient groups could benefit from a pos-
sible treatment with ω-3 PUFAs: First, LCPUFAs treatment 
could replace stimulant treatment for patients with mild forms 
of ADHD. In this patient group, side effects of stimulant 
medication outweigh the benefits. This leads to untreated 
cases of ADHD which, in turn, results in an increase in 
problems in daily life. The second group consists of patients 
who suffer both from severe ADHD and from side effects of 
the stimulant treatment. In this patient group, a combination 
of stimulant medication with ω-3 food supplements could 
reduce the given amount of stimulant medication, in order 
to reduce the suffering from side effects. Further studies are 
suggested to demonstrate the effects of food supplements 
with ω-3 LCPUFAs on ADHD symptoms.
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